U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/3/2026

1. SNOW
2. AVGO
3. RARE
4. HPE
5. FIVE
6. SPY
7. VRTS
8. NTAP
9. NTSK
10. OLLI

Go back to U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
Gilead Sciences (NASDAQ: GILD) Delayed: 151.19 +1.58 (1.06%)
Previous Close $149.61    52 Week High $108.63 
Open $150.67    52 Week Low $71.39 
Day High $151.48    P/E 83.53 
Day Low $148.41    EPS $1.81 
Volume 2,589,653